Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 12, 2016 1:12 AM ET


Company Overview of Avaxia Biologics, Inc.

Company Overview

Avaxia Biologics, Inc., a biotechnology company, develops oral antibody therapeutics. Its product pipeline comprises antibody drugs for inflammatory bowel diseases, radiation mitigations, celiac diseases, obesity and diabetes, and oral mucositis. Avaxia Biologics, Inc. has a strategic collaboration with Courtagen Life Sciences, Inc. The company was founded in 2005 and is based in Lexington, Massachusetts.

128 Spring Street

Suite 620

Lexington, MA 02421

United States

Founded in 2005





Key Executives for Avaxia Biologics, Inc.

Founder and Chief Executive Officer
Chief Operating Officer
Vice President of Technical Operations
Chief Business Officer
Age: 69
Vice President of Product Development
Age: 64
Compensation as of Fiscal Year 2015.

Avaxia Biologics, Inc. Key Developments

Avaxia Biologics, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 10:00 AM

Avaxia Biologics, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 10:00 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Barbara S. Fox, Founder and Chief Executive Officer.

Avaxia Biologics, Inc. Receives FDA Orphan Drug Designation for AVX-470 for the Treatment of Pediatric Ulcerative Colitis

Avaxia Biologics, Inc. announced that the US Food and Drug Administration (FDA) granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. AVX-470 is a gut-targeted anti-TNF antibody, which earlier this year successfully completed a Phase 1b clinical trial in adults with active ulcerative colitis. Pediatric ulcerative colitis (UC) is a serious chronic inflammatory disease of the colon. As with adult patients, children with acute UC have symptoms of rectal bleeding, diarrhea, weight loss, abdominal pain, and fever. In addition, pediatric UC patients face impaired growth and delayed puberty, as well as challenges to self-image and quality of life during the critical childhood years. Most pediatric UC patients experience more severe disease than adults, and the disease may progress more quickly in children. If drug therapy fails to control the disease, the only treatment is surgical removal of the colon (colectomy). The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders that affect fewer than 200,000 individuals within the United States. Among other benefits, Orphan Drug Designation confers a seven-year term of market exclusivity upon FDA approval. AVX-470 is the first gut-targeted anti-TNF antibody in clinical development. The lead indication is inflammatory bowel disease (IBD), a serious disease involving chronic inflammation of the intestinal tract. Currently marketed anti-TNF drugs are highly effective for the treatment of IBD. However, despite their success, these drugs have two significant drawbacks. One is that they must be infused or injected, whereas patients prefer oral medications. More importantly, they cause rare but serious side effects, such as risk of serious infection, because they dampen the immune system throughout the body, not just in the intestines where the disease occurs. As a result, these drugs are used mostly as a second- or third-line therapy, despite evidence that earlier use may improve patient outcomes. In contrast, AVX-470 is an orally administered antibody therapeutic that targets the gut, potentially improving safety and efficacy over existing anti-TNF therapies. Avaxia believes that AVX-470 has the potential to become a first-line therapy that transforms the treatment of IBD.

Avaxia Biologics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM

Avaxia Biologics, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Barbara S. Fox, Founder and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
Forticell Bioscience, Inc. United States
Editas Medicine Inc. United States
Molecular Imaging Products Company United States
Calico LLC United States
The Translational Genomics Research Institute United States

Recent Private Companies Transactions

Private Placement
July 6, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Avaxia Biologics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at